Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
First Claim
1. A method for reducing duration of common cold symptoms, said method comprising:
- nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising;
(a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3×
extract, and G. glauca 10 wt. % extract (MT);
(b) from about 0.001 wt. % to about 10 wt. % of a thickener;
(c) from about 0.001 wt. % to about 10 wt. % of a surfactant;
(d) from about 0.01 wt. % to about 10 wt. % of an organic acid;
(e) from about 0.01 wt. % to about 10 wt. % of an alkaline material;
(f) from about 0.001 wt. % to about 1 wt. % of an inhalant;
(g) from about 0.01 wt. % to about 10 wt. % of an α
-amino acid; and
(h) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition, wherein the common cold sypmtoms are selected from the group consisting of;
nasal congestion, runny nose, watery eyes, dry/scratchy throat and/or sneezing.
6 Assignments
1 Petition
Accused Products
Abstract
The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.
31 Citations
7 Claims
-
1. A method for reducing duration of common cold symptoms, said method comprising:
- nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising;
(a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3×
extract, and G. glauca 10 wt. % extract (MT);
(b) from about 0.001 wt. % to about 10 wt. % of a thickener;
(c) from about 0.001 wt. % to about 10 wt. % of a surfactant;
(d) from about 0.01 wt. % to about 10 wt. % of an organic acid;
(e) from about 0.01 wt. % to about 10 wt. % of an alkaline material;
(f) from about 0.001 wt. % to about 1 wt. % of an inhalant;
(g) from about 0.01 wt. % to about 10 wt. % of an α
-amino acid; and
(h) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition, wherein the common cold sypmtoms are selected from the group consisting of;
nasal congestion, runny nose, watery eyes, dry/scratchy throat and/or sneezing. - View Dependent Claims (2, 3, 4, 5, 6)
- nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising;
-
7. A method for reducing duration of common cold symptoms, said method comprising:
- nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising;
(a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3×
extract and G. glauca 10 wt. % extract (MT);
(b) from about 0.5 wt. % to about 1.5 wt. % of a cellulosic thickener;
(c) from about 0.01 wt. % to about 1 wt. % of a surfactant;
(d) from about 0.1 wt. % to about 1 wt. % of an organic acid;
(e) from about 0.1 to about 2 wt. % of at least one alkaline material;
(f) from about 0.001 wt. % to about 1 wt. % of an inhalant selected from the group consisting of eucalyptol, eugenol, menthol, camphor, and mixtures thereof;
(g) from about 0.05 wt. % to about 0.5 wt. % of an amino acid;
(h) from about 0.1 wt. % to about 1 wt. % sodium chloride; and
(i) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition, wherein the common cold symptoms are selected from the group consisting of;
nasal congestion, runny nose, watery eyes, dry/scratchy throat and/or sneezing.
- nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising;
Specification